Eribulin ORA is an oral formulation of eribulin. Eribulin is an anticancer agent that inhibits the growth phase of cells. Halaven® (intravenous eribulin) is approved by the FDA in to treat patients with metastatic breast cancer who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease, and to treat patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. Notably, Halaven® has shown to provide responses in patients with tumors resistant to other microtubule-targeting drugs. The U.S. FDA allowed our Investigational New Drug Application, or IND, in October 2018.